GF Fund Management
XENE icon

GF Fund Management’s Xenon Pharmaceuticals XENE Stock Holding History

GF Fund Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$81K Buy
2,179
+416
+24% +$24.7K ﹤0.01% 350
2026
Q2 		$106K Buy
1,763
+28
+2% +$1.56K ﹤0.01% 328
2026
Q1 		$101K Buy
1,735
+218
+14% +$10K ﹤0.01% 341
2025
Q4 		$68K Sell
1,517
-142
-9% -$5.96K ﹤0.01% 378
2025
Q3 		$66.6K Sell
1,659
-293
-15% -$10.3K ﹤0.01% 367
2025
Q2 		$61.1K Hold
1,952
– – ﹤0.01% 400
2025
Q1 		$65.5K Buy
1,952
+351
+22% +$13.3K ﹤0.01% 397
2024
Q4 		$62.8K Buy
+1,601
New +$66.2K ﹤0.01% 368

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capricorn Fund Managers
Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

GF Fund Management's XENE Position: Q3 2026 in Review

GF Fund Management increased its Xenon Pharmaceuticals (XENE) stake by 24% in Q3 2026, buying an estimated $24.7K and bringing the position to 2,179 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #350.

GF Fund Management first reported a position in XENE in Q4 2024 and has held it in 8 quarters since. The position peaked at $106K in Q2 2026. 116 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • GF Fund Management held 2,179 shares of Xenon Pharmaceuticals worth $81K as of Q3 2026.
  • GF Fund Management bought 416 Xenon Pharmaceuticals shares in Q3 2026, an estimated $24.7K.
  • Xenon Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #350 holding.
  • GF Fund Management first reported a position in Xenon Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • GF Fund Management's Xenon Pharmaceuticals position peaked at $106K in Q2 2026.
  • 116 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.